Sab biotherapeutics to present at the american diabetes association 84th scientific sessions

Miami, june 18, 2024 (globe newswire) -- sab biotherapeutics (nasdaq: sabs) (the “company” or “sab”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced that it will present a poster at the ada 84th scientific sessions on june 21-24, 2024 in orlando, florida. the poster will be presented by sab's senior program manager, eric sandhurst, ph.d, and published online in the journal diabetes®.
SABS Ratings Summary
SABS Quant Ranking